Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. The Indian company, Wockhardt Limited, was founded nearly four decades ago, and today claims its place amongst the country's top research and technology oriented pharmaceutical companies.

The company has subsidiaries in the United States, the United Kingdom and Brazil, and majority-owned companies in South Africa and Mexico. The company also has marketing offices in Africa, Russia, Central Asia and South East Asia. Most recently, the company entered the French market with the purchase of Negma Laboratories.

In 2003, the company launched Wosulin, a recombinant insulin product. In doing so, Wockhardt became the fourth company, and first Asian manufacturer, to be able to offer the product. Wockhardt has identified biopharmaceuticals as a major developing market area, and is making plans to sell generic biopharmaceuticals in the US and EU once regulatory pathways have been established.